These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1666 related items for PubMed ID: 18550998

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG.
    Arch Intern Med; 2006 Apr 10; 166(7):787-96. PubMed ID: 16606817
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients.
    Baer JT, Sauer WH, Berlin JA, Kimmel SE.
    Am J Cardiol; 2004 Aug 15; 94(4):479-81. PubMed ID: 15325933
    [Abstract] [Full Text] [Related]

  • 15. High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Anderson RE, Pfeffer MA, Thune JJ, McMurray JJ, Califf RM, Velazquez E, White HD, Rouleau JL, Skali H, Maggioni A, Solomon SD.
    Am Heart J; 2008 Apr 15; 155(4):706-11. PubMed ID: 18371480
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
    Andraws R, Brown DL.
    Am J Cardiol; 2007 Apr 01; 99(7):1006-12. PubMed ID: 17398202
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin receptor blockers in hypertension. New insights from Japan.
    Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G.
    Hypertens Res; 2010 May 01; 33(5):394-7. PubMed ID: 20150909
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 84.